- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00648232
HIV Counseling and Testing and Linkage to Care in Uganda
Descripción general del estudio
Estado
Condiciones
Descripción detallada
HIV is a virus that can lead to acquired immunodeficiency syndrome (AIDS), a disease that breaks down the immune system and allows for entry of life-threatening secondary infections. HIV is a major global health concern, with countries in Africa undergoing a severe HIV/AIDS crisis. The number of new cases of HIV infection in Africa continues to rise, making disease prevention methods imperative. Important to the prevention process are early testing, educational counseling on HIV and how to reduce sexual-risk behavior, and connecting people with HIV infection to services that offer medical treatment and social support. However, the most effective strategy for fully integrating HIV counseling, testing, and medical care access is not known. This study will compare the effectiveness of brief versus detailed HIV counseling sessions, paired with either referrals to HIV-specific medical care or usual care, in reducing HIV risk behavior and in increasing treatment adherence in Uganda.
Participation in this study will last 12 months. All participants will undergo an initial interview to obtain basic information on previous HIV testing and status. Participants will then be assigned randomly to receive a brief or more detailed counseling session given before and after HIV testing. Participants assigned to the brief counseling session will receive 10 to 15 minutes of pretest counseling on the importance of HIV testing and available services for people infected with HIV. Participants assigned to the detailed counseling session will receive 45 to 60 minutes of pretest counseling on general HIV/AIDS information and testing for HIV. After pretest counseling, participants in both groups will undergo a blood draw for HIV testing. All participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
Participants who are found to be infected with HIV will be assigned randomly to receive enhanced referrals to HIV-specific medical care or referrals to usual care. Participants receiving the enhanced referrals will be provided with more detailed counseling on how to access HIV services, will be introduced to a specific HIV clinic, and will be given a list of other HIV services available in the area. After leaving the hospital, participants will receive reminder telephone calls 1 week before their first scheduled visits at the HIV clinics. Participants receiving referrals to usual care will be provided with information on the importance of receiving HIV care and will be given a list of available HIV area services. At Months 3, 6, 9, and 12, participants in both groups will be interviewed about contact information, overall health, current medications, sexual history, health services utilized, and any repeat HIV tests. Participants who are not infected with HIV may be randomly selected to undergo the same follow-up interviews as the HIV infected participants.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Kampala, Uganda, 7072
- Makerere University/Mulago Teaching Hospital, Uganda
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Willing to receive HIV test results
- Willing to provide adequate contact information
- Possesses sufficient cognitive ability to provide informed consent and participate in the interventions, as determined subjectively by the Regulatory Coordinator (patient with altered mental status or who is otherwise too ill to participate in the consent process will be excluded)
- Planned local residence over the next year after study entry (within a reasonable distance; approximate radius of 25 km of Kampala city center)
- Fluent in Luganda or English
Exclusion Criteria:
- Self-reported HIV-infected serostatus (defined as ever receiving an HIV-positive test result)
- Self-reported HIV test within the 12 months before study entry
- Any condition that, in the opinion of the study staff, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: A
Participants will receive voluntary brief HIV counseling and testing plus enhanced linkage to care.
|
Participants will receive 10 to 15 minutes of pretest counseling on the importance of HIV testing and on available services for people infected with HIV.
After pretest counseling, participants will undergo a blood draw for HIV testing.
Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
Participants will be provided with more detailed counseling on how to access HIV services, will be introduced to a specific HIV clinic, and will be given a list of other HIV services available in the area.
After leaving the hospital, participants will receive reminder telephone calls 1 week before their scheduled visits at the HIV clinics.
|
|
Experimental: B
Participants will receive voluntary brief HIV counseling and testing plus routine referral to care.
|
Participants will receive 10 to 15 minutes of pretest counseling on the importance of HIV testing and on available services for people infected with HIV.
After pretest counseling, participants will undergo a blood draw for HIV testing.
Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
Participants will be provided with information on the importance of receiving HIV care and will be given a list of available HIV area services.
|
|
Experimental: C
Participants will receive voluntary longer, more detailed HIV counseling and testing plus enhanced linkage to care.
|
Participants will be provided with more detailed counseling on how to access HIV services, will be introduced to a specific HIV clinic, and will be given a list of other HIV services available in the area.
After leaving the hospital, participants will receive reminder telephone calls 1 week before their scheduled visits at the HIV clinics.
Participants will receive 45 to 60 minutes of pretest counseling on general HIV/AIDS information and testing for HIV.
After pretest counseling, participants will undergo a blood draw for HIV testing.
Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
|
|
Experimental: D
Participants will receive voluntary longer, more detailed HIV counseling and testing plus routine referral to care.
|
Participants will be provided with information on the importance of receiving HIV care and will be given a list of available HIV area services.
Participants will receive 45 to 60 minutes of pretest counseling on general HIV/AIDS information and testing for HIV.
After pretest counseling, participants will undergo a blood draw for HIV testing.
Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
|
|
Comparador activo: E
Participants who are found to be healthy will receive voluntary brief HIV counseling and testing only.
|
Participants will receive 10 to 15 minutes of pretest counseling on the importance of HIV testing and on available services for people infected with HIV.
After pretest counseling, participants will undergo a blood draw for HIV testing.
Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
|
|
Comparador activo: F
Participants who are found to be healthy will receive voluntary longer, more detailed HIV counseling and testing only.
|
Participants will receive 45 to 60 minutes of pretest counseling on general HIV/AIDS information and testing for HIV.
After pretest counseling, participants will undergo a blood draw for HIV testing.
Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Reduction in HIV risk behavior among inpatients after discharge
Periodo de tiempo: Measured at Months 3, 6, 9, and 12
|
Measured at Months 3, 6, 9, and 12
|
|
Receipt of opportunistic infection (OI) prophylaxis, adherence to antiretroviral therapy (ART), and reduction in mortality
Periodo de tiempo: Measured at Months 3, 6, 9, and 12
|
Measured at Months 3, 6, 9, and 12
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Number of infections averted per patient randomized to each of the four intervention strategies
Periodo de tiempo: Measured at Month 12
|
Measured at Month 12
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Thomas J. Coates, PhD, UCLA David Geffen School of Medicine
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Enfermedades de transmisión sexual
- Infecciones por lentivirus
- Infecciones por retroviridae
- Síndromes de deficiencia inmunológica
- Enfermedades del sistema inmunológico
- Infecciones por VIH
Otros números de identificación del estudio
- R01MH077512 (Subvención/contrato del NIH de EE. UU.)
- DABHR 9A-ASGA
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .